Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $111.59 Average PT from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Buy” by the twenty ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $111.50.

Several analysts have recently commented on ALNY shares. UBS Group increased their price target on shares of Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, September 4th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 price target on the stock. in a research report on Wednesday, September 18th. Nomura set a $62.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “sell” rating in a research report on Tuesday, October 8th. Finally, Barclays restated a “buy” rating and set a $125.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 49,456 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, October 14th. The shares were sold at an average price of $79.45, for a total value of $3,929,279.20. Following the transaction, the chief executive officer now owns 239,449 shares in the company, valued at approximately $19,024,223.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Barry E. Greene sold 58,913 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the completion of the transaction, the president now owns 111,851 shares in the company, valued at approximately $10,065,471.49. The disclosure for this sale can be found here. 3.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,316,686 shares of the biopharmaceutical company’s stock valued at $676,018,000 after acquiring an additional 657,595 shares during the period. BlackRock Inc. raised its stake in shares of Alnylam Pharmaceuticals by 1.7% in the 2nd quarter. BlackRock Inc. now owns 6,537,253 shares of the biopharmaceutical company’s stock valued at $474,340,000 after acquiring an additional 109,126 shares during the period. Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock valued at $450,850,000 after acquiring an additional 528,966 shares during the period. Maverick Capital Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 31.9% in the 2nd quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock valued at $307,365,000 after acquiring an additional 1,025,629 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,508,614 shares of the biopharmaceutical company’s stock valued at $254,585,000 after acquiring an additional 25,025 shares during the period. Institutional investors own 93.51% of the company’s stock.

NASDAQ ALNY traded up $1.59 during trading hours on Monday, hitting $92.05. The company had a trading volume of 362,900 shares, compared to its average volume of 602,539. The business has a 50 day moving average of $84.86 and a 200-day moving average of $78.13. The company has a market cap of $10.10 billion, a PE ratio of -12.16 and a beta of 2.37. Alnylam Pharmaceuticals has a 1-year low of $60.27 and a 1-year high of $96.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.25. The business had revenue of $70.06 million for the quarter, compared to analyst estimates of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The company’s quarterly revenue was up 3284.5% on a year-over-year basis. During the same period in the prior year, the business earned ($1.56) earnings per share. Sell-side analysts expect that Alnylam Pharmaceuticals will post -7.9 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: What is meant by a buy rating?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.